R-Tech Ueno Ltd., of Tokyo, said it received orphan drug designation from Japanese regulators for unoprostone isopropyl for the treatment of retinitis pigmentosa. An ophthalmic solution version of unoprostone is in phase III testing. R-Tech licensed U.S. and Canadian rights to the drug to Sucampo Pharmaceuticals Inc., of Bethesda, Md., in 2009 and expanded the deal in 2011 to include the rest of the world, except for R-Tech's territories of Japan, South Korea, Taiwan and China.